Key facts
- This page summarizes Cenk Sumen's Form 4 filing for MAXCYTE, INC. (MXCT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Mar 2023, 16:41.
Cenk Sumen - 11 Apr 2022 Form 4 Insider Report for MAXCYTE, INC. (MXCT)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- MXCT
- Reported as of
- 11 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Mar 2023, 16:41:26 UTC
- Prior SEC filing
- 17 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian F. Leaf, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Cenk Sumen filed Form 4 for MAXCYTE, INC. (MXCT) on 21 Mar 2023.
Change
- Previous filing in this sequence was filed on 17 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MXCT
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +500,000
- Change %
- Price
- $0.000000
- Shares after
- 500,000
- Date
- 11 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $5.70
- Footnotes
- F1, F2
MXCT
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- Price
- $0.000000
- Shares after
- 120,000
- Date
- 20 Mar 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 120,000
- Exercise price
- $4.19
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
As announced in a press release by the issuer on April 15, 2022, on April 11, 2022 the Issuer awarded a stock option to the Reporting Person as a material inducement to his employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted under the Issuer's 2021 Inducement Plan. However, due to an administrative oversight, the stock option grant was not previously reported on a Form 4 as required and is being reported on this report.
Footnote F2
25% of the shares underlying this option vest on April 11, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.
Footnote F3
25% of the shares underlying this option vest on March 20, 2024 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.